VKTX Live signals | Maximize Profits with Getagraph.com

SELL 1125 min ago

@ $63.72

Issued: 19 Apr 2024 @ 15:55

Return: -0.47%

Previous signal: Apr 17 - 10:09

Previous signal: Buy

Return: -5.35 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):
Our systems believe the stock currently is overvalued by 1.29% compare to its pairs and should correct downwards.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders...

Stats
Today's Volume	3.04M
Average Volume	6.45M
Market Cap	6.94B
EPS	$0 ( 2024-02-14 )
Next earnings date	( $-0.270 ) 2024-04-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-69.69
ATR14	$4.11 (6.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Mancini Marianna	Buy	31 667	Common Stock, par value $0.00001 per share
2024-03-27	Mancini Marianna	Sell	16 610	Common Stock, par value $0.00001 per share
2024-03-27	Lian Brian	Buy	221 667	Common Stock, par value $0.00001 per share
2024-03-27	Lian Brian	Sell	153 948	Common Stock, par value $0.00001 per share
2024-03-27	Zante Greg	Buy	31 667	Common Stock, par value $0.00001 per share

INSIDER POWER
10.03
Last 100 transactions
Buy: 2 960 710 \| Sell: 2 536 561

Correlation (AI algo v.1.1b): Overvalued: -1.29% $62.63 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.92 (very strong)

Short: -0.81 (strong negative)

Signal:(56) Neutral

Viking Therapeutics Inc Correlation

10 Most Positive Correlations
CFFE	0.97
ARIZ	0.966
EMLD	0.96
ARTEU	0.96
AIB	0.958
GENQ	0.956
FTII	0.956
GDST	0.955
ACLS	0.955
BRAC	0.954

10 Most Negative Correlations
SMFL	-0.968
NCBS	-0.963
MYSZ	-0.96
PIII	-0.958
CREG	-0.955
BCAB	-0.95
SPCX	-0.949
KTTA	-0.948
TRIT	-0.947
VFF	-0.947

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Viking Therapeutics Inc Correlation - Currency/Commodity

0.58
( weak )

0.42
( neutral )

0.72
( moderate )

-0.82
( strong negative )

-0.77
( moderate negative )

-0.12
( neutral )

Viking Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-292 000 (0.00 %)
EPS:	$-0.910

Q4	2023
Revenue:	$0
Gross Profit:	$-74 000.00 (0.00 %)
EPS:	$-0.250

Q3	2023
Revenue:	$0
Gross Profit:	$-73 000.00 (0.00 %)
EPS:	$-0.230

Q2	2023
Revenue:	$0
Gross Profit:	$-73 000.00 (0.00 %)
EPS:	$-0.190

Financial Reports:

No articles found.

Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Realtime updates for Viking Therapeutics Inc [VKTX]

Upcoming Earnings Alert